COMMUNIQUÉS West-GlobeNewswire

IBA Selected to Install Five-room Proton Therapy System in Shenzhen, China
29/03/2019
IBA Selected to Install Five-room Proton Therapy System in Shenzhen, China Final contract negotiations for the public tender will start in the coming weeks Louvain-la-Neuve, Belgium, 29 March, 2019 - IBA ( Ion Beam [...]
IBA VEND DEUX PREMIERS ACCÉLÉRATEURS RHODOTRON® À NORTHSTAR MEDICAL RADIOISOTOPES
29/03/2019
Le contrat signé porte sur huit machines Six autres machines seront livrées dans les prochaines années Louvain-la-Neuve, Belgique, le 29 mars 2019 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de [...]
IBA SELLS FIRST TWO RHODOTRON® ACCELERATORS TO NORTHSTAR MEDICAL RADIOISOTOPES
29/03/2019
Total contract signed for eight systems Six others to be delivered over the coming years Louvain-La-Neuve, Belgium, March 29 th , 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton [...]
Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders
29/03/2019
Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Genkyotex Reverse Stock Split Takes Effect
29/03/2019
Completion of the 10-for-1 reverse stock split Technical change has no impact on value of shares held by shareholders GKTX ticker on Euronext remains unchanged ARCHAMPS, France, March 29, 2019 (GLOBE NEWSWIRE) -- [...]
Prise d’effet du regroupement d’actions de Genkyotex
29/03/2019
Finalisation du regroupement d’actions par 10 Cet ajustement technique est sans impact sur la valeur des titres Genkyotex détenus par les actionnaires Le code mnémonique reste inchangé (GKTX) ARCHAMPS, France, 29 mars [...]
Innovate Phytotechnologies Inc. (CSE:“INVP”) Conditional Listing Acceptance
29/03/2019
Cannabis Industry Research and Analysis leader to complete Amalgamation with Ross River Minerals Inc. VANCOUVER, British Columbia, March 28, 2019 (GLOBE NEWSWIRE) -- Innovate Phytotechnologies Inc. (“Innovate or The [...]
CrownBio and Hubrecht Organoid Technology Announce a Strategic Partnership, including Exclusive License to Provide Oncology Organoid-Based Preclinical Drug Development and Validation Services
29/03/2019
Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform SAN DIEGO, March 28, 2019 (GLOBE NEWSWIRE) -- Crown [...]
MedMira Reports 2018 Fourth Quarter and Year End Financial Results
29/03/2019
HALIFAX, Nova Scotia, March 28, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the financial year ended July 31, 2018. Profit and Loss Highlights Revenue: The [...]
Surgery Partners Announces Pricing of New Note Offering
28/03/2019
NASHVILLE, Tenn., March 28, 2019 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners”) a leading provider of surgical services, today announced that its wholly-owned subsidiary, Surgery Center [...]
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28/03/2019
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 [...]
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28/03/2019
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 [...]
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS
28/03/2019
-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile Consistent With Previously Reported Results -- [...]
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY
28/03/2019
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response -- -- Significant Inhibition of Radiographic Progression [...]
Align Technology and Straumann Group Settle Global ClearCorrect Patent Disputes and Sign Non-Binding Letter of Intent for Straumann to Distribute iTero Scanners
28/03/2019
Straumann agrees to immediate payment of $35 million settlement to Align Align and Straumann to dismiss existing patent disputes in US and UK Neodent to withdraw Brazil invalidity action against Align Align and [...]
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
28/03/2019
- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 – - Plan to initiate phase I study with intranasal racemic ketamine in Suicidality-PTSD in the [...]
Genfit: GENFIT Announces the Exercise in Full of the Option Granted to the Underwriters of its Global Offering and Nasdaq Global Select Market Listing to Purchase up to 997,500 Additional ADSs
28/03/2019
FOR IMMEDIATE RELEASE GENFIT Announces the Exercise in Full of the Option Granted to the Underwriters of its Global Offering and Nasdaq Global Select Market Listing to Purchase up to 997,500 Additional ADSs Gross [...]
Genfit : GENFIT annonce l’exercice intégral de l’option de surallocation dans le cadre de son introduction en bourse aux États-Unis
28/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study
28/03/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it [...]

Pages